SCHEMBL3732473

SCHEMBL3732473

CN1CC=CC=C1C(=O)O

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.32
CRHR2 Q13324 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15262149 0.83
SCHEMBL1845751 0.83
SCHEMBL8855765 0.81 PARP1 (0.31)
SCHEMBL26015677 0.78 BAZ2B (0.33) CRHBPCRHR2
SCHEMBL12443797 0.78 CRHBP (0.41) CRHBPCRHR2
SCHEMBL9442011 0.77 ALDH1A1 (0.43)
SCHEMBL9789898 0.77
SCHEMBL16241310 0.76 MAPT (0.31)
SCHEMBL16774650 0.75
SCHEMBL18496198 0.72 CRHBP (0.33) CRHBPCRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5622944-A MODIFIED 17-HYDROXY STEROL; TRANSDERMAL ELECTROTRANSPORT ENHANCEMENT AFFYMAX TECHNOLOGIES N.V. (GB) 1997-04-22 US claimed
JP-5194113-A None JP disclosed
US-11020438-B2 Phospholipid compositions and their preparation AKER BIOMARINE ANTARCTIC AS (NO) 2021-06-01 US disclosed
US-10960016-B2 Capsules containing high doses of krill phospholipids AKER BIOMARINE ANTARCTIC AS (NO) 2021-03-30 US disclosed
EP-3094337-B1 PHOSPHOLIPID COMPOSITIONS AND THEIR PREPARATION AKER BIOMARINE ANTARCTIC AS (NO) 2021-03-24 EP disclosed
US-10806742-B2 Liquid phospholipid-containing compositions for the preparation of pharmaceuticals AKER BIOMARINE ANTARCTIC AS (NO) 2020-10-20 US disclosed
US-20200016214-A1 PHOSPHOLIPID COMPOSITIONS AND THEIR PREPARATION AKER BIOMARINE HUMAN INGREDIENTS AS (NO) 2020-01-16 US disclosed
US-20180133263-A1 PHOSPHOLIPID COMPOSITIONS AND THEIR PREPARATION AKER BIOMARINE ANTARCTIC AS (NO) 2018-05-17 US disclosed
US-9867856-B2 Phospholipid compositions and their preparation AKER BIOMARINE ANTARCTIC AS (NO) 2018-01-16 US disclosed
US-20170182074-A1 LIQUID PHOSPHOLIPID-CONTAINING COMPOSITIONS FOR THE PREPARATION OF PHARMACEUTICALS AKER BIOMARINE HUMAN INGREDIENTS AS (NO) 2017-06-29 US disclosed
WO-2015121381-A1 CAPSULES CONTAINING HIGH DOSES OF KRILL PHOSPHOLIPIDS AKER BIOMARINE ANTARCTIC AS (NO) 2015-08-20 WO disclosed
WO-2015121378-A1 LIQUID PHOSPHOLIPID-CONTAINING COMPOSITIONS FOR THE PREPARATION OF PHARMACEUTICALS AKER BIOMARINE ANTARCTIC AS (NO) 2015-08-20 WO disclosed
WO-2015104401-A1 PHOSPHOLIPID COMPOSITIONS AND THEIR PREPARATION AKER BIOMARINE ANTARCTIC AS (NO) 2015-07-16 WO disclosed
EP-2114462-B1 Compounds for fluorescence imaging UNIV GENEVE (CH) 2013-06-05 EP disclosed
US-20100278745-A1 COMPOUNDS FOR FLUORESCENCE IMAGING UNIVERSITE DE GENEVE (CH) 2010-11-04 US disclosed
EP-2114462-A2 COMPOUNDS FOR FLUORESCENCE IMAGING UNIVERSITE DE GENEVE (CH) 2009-11-11 EP disclosed
WO-2008078190-A2 COMPOUNDS FOR FLUORESCENCE IMAGING UNIVERSITE DE GENEVE (US) 2008-07-03 WO disclosed
EP-1241522-A1 Processing method for silver halide color photographic material Fuji Photo Film Co., Ltd. (JP) 2002-09-18 EP disclosed
US-5622944-A MODIFIED 17-HYDROXY STEROL; TRANSDERMAL ELECTROTRANSPORT ENHANCEMENT AFFYMAX TECHNOLOGIES N.V. (GB) 1997-04-22 US disclosed
JP-H05194113-A ANTIFOULING AGENT KAIYO BIO TECHNOL KENKYUSHO:KK 1993-08-03 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170182074-A1 LIQUID PHOSPHOLIPID-CONTAINING COMPOSITIONS FOR THE PREPARATION OF PHARMACEUTICALS PHOSPHO1, PLTP, LIPA CRHBP 3028/4885CRHR2 4508/4885
US-20200016214-A1 PHOSPHOLIPID COMPOSITIONS AND THEIR PREPARATION PHOSPHO1, PLTP, PLIN5 CRHBP 2315/4885CRHR2 4675/4885
US-20180133263-A1 PHOSPHOLIPID COMPOSITIONS AND THEIR PREPARATION PHOSPHO1, PLTP, PLIN5 CRHBP 2315/4885CRHR2 4675/4885
US-10806742-B2 Liquid phospholipid-containing compositions for the preparation of pharmaceuticals PHOSPHO1, PLTP, LIPA CRHBP 3028/4885CRHR2 4508/4885
US-11020438-B2 Phospholipid compositions and their preparation PHOSPHO1, PLTP, PLIN5 CRHBP 2315/4885CRHR2 4675/4885
US-10960016-B2 Capsules containing high doses of krill phospholipids PHOSPHO1, PLIN5, SGMS2 CRHBP 1671/4885CRHR2 3479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.